positive
Recently
Cellatrix Secures $30 Million Series B to Advance Rare Disease Gene Therapies
No Image
Cellatrix raised $30 million to develop gene therapies for rare disorders, expanding India’s biotech innovation and advancing clinical readiness timelines.
Bangalore-based biotech startup Cellatrix raised $30 million in Series B funding led by international venture investors, with participation from strategic healthcare funds. The capital will support development of next-generation gene therapies targeting rare genetic disorders and expand preclinical research facilities. Management said proceeds will accelerate IND filings and enable manufacturing scale-up under global regulatory compliance. Analysts highlighted India’s growing biotech funding ecosystem as a catalyst for translational medicine. The company aims to enter clinical trials for its lead candidate within 18 months.